University at Buffalo Scientist is Co-author on NEJM Paper Demonstrating How an Oral Microbiome Therapy Prevents Recurrent C. Difficile Infections
March 03, 2022
March 03, 2022
BUFFALO, New York, March 3 (TNSJou) -- The University at Buffalo (State University of New York) issued the following news release:
People who develop colitis with the virulent bacterium C. difficile, usually after a course of antibiotics or chemotherapy, experience severe diarrhea, inflammation of the colon and abdominal pain. Each year, nearly half a million Americans suffer from it. About 1 in 6 will go on to experience a relapse and sometimes it continues to recur. C. difficile i . . .
People who develop colitis with the virulent bacterium C. difficile, usually after a course of antibiotics or chemotherapy, experience severe diarrhea, inflammation of the colon and abdominal pain. Each year, nearly half a million Americans suffer from it. About 1 in 6 will go on to experience a relapse and sometimes it continues to recur. C. difficile i . . .